Dr. Thomas VanCott, president and chief executive officer of ABL, said, “ABL has expanded to meet increasing demand for high quality product development and manufacturing services in the local and international biopharmaceutical communities. We will continue to work closely with our clients to accelerate the advance of discoveries to clinical testing by leveraging 50 years of scientific expertise combined with the benefits of this new facility.”